CiVentiChem, a CDMO, has completed a new facility, significantly expanding its manufacturing capacity by 300%. This state-of-the-art facility will focus on producing Regulatory Starting Materials (RSMs) and intermediates to support small molecule clinical and commercial needs.   “It’s a major evolution for the company,” said Bhaskar Venepalli, CEO of CiVentiChem. “The decision to invest in a second manufacturing plant was driven by our customers and recent international developments. We’ve see...